Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.

MLA

Zhang, Juan, et al. “Impact of the Addition of Carboplatin to Anthracycline-Taxane-Based Neoadjuvant Chemotherapy on Survival in BRCA1/2-Mutated Triple-Negative Breast Cancer.” International Journal of Cancer, vol. 148, no. 4, Feb. 2021, pp. 941–49. EBSCOhost, https://doi.org/10.1002/ijc.33234.

APA

Zhang, J., Yao, L., Liu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2021). Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer. International Journal of Cancer, 148(4), 941–949. https://doi.org/10.1002/ijc.33234

Chicago

Zhang, Juan, Lu Yao, Yiqiang Liu, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, and Yuntao Xie. 2021. “Impact of the Addition of Carboplatin to Anthracycline-Taxane-Based Neoadjuvant Chemotherapy on Survival in BRCA1/2-Mutated Triple-Negative Breast Cancer.” International Journal of Cancer 148 (4): 941–49. doi:10.1002/ijc.33234.